IMRX — Immuneering Income Statement
0.000.00%
Last trade - 00:00- $44.62m
- $8.48m
- 17
- 32
- 26
- 13
Annual income statement for Immuneering, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.31 | 2.08 | 0.317 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 1.03 | 0.927 | 0.159 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 19.4 | 36 | 52.1 | 58.4 | 64.1 |
| Operating Profit | -17.1 | -33.9 | -51.7 | -58.4 | -64.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17 | -33.8 | -50.5 | -53.5 | -61 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17 | -33.5 | -50.5 | -53.5 | -61 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17 | -33.5 | -50.5 | -53.5 | -61 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17 | -33.5 | -50.5 | -53.5 | -61 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.699 | -2.46 | -1.91 | -1.88 | -2.04 |
| Dividends per Share |